Efficacy of methylprednisolone and urokinase pulse therapy combined with or without cyclophosphamide in severe Henoch-Schoenlein nephritis: A clinical and histopathological study

Nephrology Dialysis Transplantation

Volumn 19, Issue 4, 2004, Pages 858-864

  Kawasaki, Yukihiko ^a   Suzuki, Junzo ^a   Suzuki, Hitoshi ^a  

^a FUKUSHIMA MEDICAL UNIVERSITY   (Japan)

Author keywords

Cyclophosphamide; HSPN; Methylprednisolone pulse therapy; Urokinase pulse therapy

Indexed keywords

ANTIBIOTIC AGENT; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DIPYRIDAMOLE; HEPARIN; IMMUNOSUPPRESSIVE AGENT; METHYLPREDNISOLONE; NIFEDIPINE; PREDNISOLONE; UROKINASE; WARFARIN;

ANAPHYLACTOID PURPURA; ARTICLE; BONE MARROW SUPPRESSION; BRONCHITIS; CHRONICITY; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; CUSHINGOID SYNDROME; DISEASE SEVERITY; DRUG EFFICACY; DRUG PULSE THERAPY; DRUG WITHDRAWAL; GLAUCOMA; GROWTH RETARDATION; HEMORRHAGIC CYSTITIS; HISTOPATHOLOGY; HUMAN; HYPERTENSION; INFECTION; INTERSTITIAL PNEUMONIA; KIDNEY BIOPSY; KIDNEY DISEASE; LEUKOPENIA; LOBAR PNEUMONIA; NEPHRITIS; PRIORITY JOURNAL; PROTEIN URINE LEVEL; RETROSPECTIVE STUDY; STATISTICAL ANALYSIS;

BIOPSY; CHILD; CYCLOPHOSPHAMIDE; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFUSIONS, INTRAVENOUS; KIDNEY; MALE; METHYLPREDNISOLONE; NEPHRITIS; PURPURA, SCHOENLEIN-HENOCH; RETROSPECTIVE STUDIES; TIME FACTORS; URINARY PLASMINOGEN ACTIVATOR;

EID: 1842418636     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/ndt/gfg617     Document Type: Article

References (29)

1. Habib R, Niaudet R, Levy M. Schoenlein-Henoch purpura nephritis and IgA nephropathy. In: Tisher CC, Brenner BM, eds. Renal Pathology with Clinical and Functional Correlations, 2nd Edn. Lippincott, Philadelphia, 1994; 427-523
2. Haycock GB. The nephritis of Henoch-Schoenlein purpura. In: Cameron JS, ed. Oxford Textbook of Nephrology, 2nd Edn. Oxford University Press, Oxford, 1998; 585-612
3. Niaudet P, Habib R. Methylprednisolone pulse therapy in the treatment of severe forms of Schoenlein-Henoch purpura nephritis. Pediatr Nephrol 1998; 12: 238-243
4. Watanabe T, Takahashi S, Nakajo S, Hamasaki M. Pathological improvement of IgA nephropathy and Henoch-Schoenlein purpura nephritis with urokinase therapy. Acta Paediatr Japonica 1996; 38: 622-628
5. Coppo R, Mazzucco G, Cagnoli L, Lupo A, Schena P, for the Italian Group of Renal Immunopathology Collaborative Study on Henoch-Schönlein purpura. Long-term prognosis of Henoch-Schoenlein nephritis in adults and children. Nephrol Dial Transplant 1997; 12: 2277-2283
6. Counahan R, Winterborn MH, White RHR et al. Prognosis of Henoch-Schoenlein nephritis in children. Br Med J 1977; 2: 11-14
7. Iijima K, Ito-Kariya S, Nakamura H, Yoshikawa N. Multiple combined therapy for severe Henoch-Schoenlein nephritis in children. Pediatr Nephrol 1998; 12: 244-248
8. Foster BJ, Bernaro C, Drummono KN, Sbarma AK. Effective therapy for severe Henoch-Schoenlein purpura nephritis with prednisone and azathioprine: A clinical and histopathologic study. J Pediatr 2000; 136: 370-375
9. Flynn JT, Smoyer WE, Bunchman TE, Kershaw DB, Sedman A. Treatment of Henoch-Schoenlein purpura glomerulonephritis in children with high-dose corticosteroids plus oral cyclophosphamide. Am J Nephrol 2001; 21: 128-133
10. Oner A, Tinaztepe K, Erdogan O. The effect of triple therapy on rapidly progressive type of Henoch-Schönlein nephritis. Pediatr Nephrol 1995; 9: 6-10
11. Kawasaki Y, Suzuki J, Nozawa R, Suzuki S, Suzuki H. Efficacy of methylprednisolone and urokinase pulses therapy for severe Henoch-schoenlein nephritis. Pediatrics 2003; 111: 785-789
12. Southwest Pediatric Nephrology Study Group. A clinico-pathologic study of crescentic glomerulonephritis in 50 children. A report of the Southwest Pediatric Nephrology Study Group. Kidney Int 1985; 27: 450-458
13. National Heart, Lung and Blood Institute, Bethesda, Maryland. Report of the Second Task Force on Blood Pressure Control in Children. Pediatrics 1987; 79: 1-25
14. Yoshikawa N, Ito H, Yoshiya K et al. Henoch-Schoenlein nephritis and IgA nephropathy in children: A comparison of clinical course. Clin Nephrol 1987; 27: 33-237
15. Diasio RB, Lo Buglio AF. Immunomodulators: Immunosuppressive agents and immunostimulants. In: Hardman JG, Limbird LE, eds. Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th Edn. McGraw-Hill, New York, 1996; 1291-1308
16. Taube D, Brown Z, Williams DG. Long-term impairment of suppressor-cell function by cyclophosphamide in minimal-change nephropathy and its association with therapeutic response. Lancet 1981; 1: 235-238
17. Feehally J, Beattie TJ, Brenchley PEC et al. Modulation of cellular immune function by cyclophosphamide in children with minimal-change nephropathy. N Engl J Med 1984; 310: 415-420
18. Berns JS, Gaudio KM, Krassner LS et al. Steroid-responsive nephritic syndrome of childhood: A long-term study of the clinical course, histopathology, efficacy of cyclophosphamide therapy, and effects on growth. Am J Kidney Dis 1987; 9: 108-114
19. Luqmani RA, Palmer RG, Bacon PA. Azathioprine, cyclophophamide and chlorambucil. Baillieres Clin Rheumatol 1990; 4: 595-619
20. Nachman PH, Hogan SL, Jennette JC, Falk RJ. Treatment response and relapse in antineutrophil cytoplasmic autoantibody-associated microscopic polyangitis and glomerulonephritis. J Am Soc Nephrol 1996; 7: 33-39
21. Imai H, Kodama T, Yasuda T, Nakamoto Y, Miura AB. Inverse relationship between serum cholinesterase activity and the administration of cyclophosphamide: An index of cyclophosphamide therapy. Nephrol Dial Transplant 1995; 9: 1240-1249
22. Yanagida M, Arai H, Nakano T et al. Gas6 induces mesangial vell proliferation via latent transcription factor STAT3. J Biol Chem 2001; 276: 42364-42369
23. Humair L, Kwaan HC, Potter EV. The role of fibrinogen in renal disease. Effect of anticoagulants and urokinase on experimental lesions in mice. J Lab Clin Med 1969; 74: 72
24. Tajima H, Ishiguro J, Nonaka R, Kurita M, Tanaka S, Ogawa N. Metabolic fate of urokinase. Clin Pharm Bull 1974; 22: 727
25. Glass WF, Radnik RA, Garoni JA, Kreisberg JI. Urokinase-dependent adhesion loss and shape change after cyclic adenosine monophosphate elevation in cultured rat mesangial cells. J Clin Invest 1988; 82: 1922-1936
26. Yasunaga C, Nakashima Y, Sueishi K. A role of fibrinolytic activity in angiogenesis: Quantitative assay using in vitro method. Lab Invest 1989; 61: 698-710
27. Hillis GS, Duthie LA, MacLeod AM. Dipyridamole inhibiys human mesangial cell proliferation. Nephron 1998; 78: 172-178
28. Nagai K, Arai H, Doi T et al. Growth arrest-specific gene 6 is involved in glomerular hypertrophy in the early stage of diabetic nephropathy. J Biol Chem 2003; 278: 18229-18234
29. Lee GSL, Choong HL, Chiang GSC, Woo KT. Three-year randomized controlled trial of dipyridamole and low-dose warfarin in patients with IgA nephropathy and renal impairment. Nephrology 1997; 3: 117-121